Electron News and Research

RSS

Study identifies small molecule inhibitors of SARS-CoV-2 which block key cellular kinases

Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.

28 Jun 2020

Mathematical model reveals the risk of SARS-CoV-2 infection after fecal microbiota transplantation

In their new paper available on the bioRxiv* preprint server, US researchers from the OpenBiome nonprofit organization used a mathematical model to simulate the usefulness of different testing strategies for fecal samples and showed that the probability of releasing a fecal microbiota donation with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is low when several important variables are taken into account.

28 Jun 2020

Interactive cloud-based data portal provides access to treasure trove of pediatric solid tumor data

An innovative, interactive cloud-based data portal debuted this week that lets academic researchers mine the world's largest and most comprehensive collection of scientific resources for studying pediatric solid tumors and their related biology.

26 Jun 2020

Study shows how two proteins provide a tunnel for bad cholesterol to enter the cells

A study has outlined how two proteins are instrumental to bringing cholesterol into cells – a finding that has implications for a range of diseases.

26 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

SARS-CoV-2 can replicate in human pediatric gastric organoids

A diverse research group from the United Kingdom, Italy, China, and Australia established a first expandable human gastric organoid culture across fetal developmental stages, supporting the hypothesis that fetal tissue seems to be much less susceptible to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection – especially in the early stages of development.

25 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

Structured 'cut-and-paste' design enables streamlined development of SARS-CoV-2 molecular probes

A seminal study by US researchers, currently available on the bioRxiv* preprint server, demonstrates how structure-based design can be efficiently employed to develop molecular probes targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and its domains, with possible future use in diagnostics, treatment and vaccine development.

24 Jun 2020

Abnormal findings in testicular tissue of COVID-19 patients, SARS-CoV-2 mostly undetected

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 9.263 million cases and taken more than 477,000 lives as of June 24, 2020 – just six months after the initial outbreak in Wuhan, China, was reported. The illness, called COVID-19 disease, caused by SARS-CoV-2 is a severe pneumonic illness, caused by the entry of the virus into the type II alveolar cells.

24 Jun 2020

Discovery provides a potential target for infectious diseases immunotherapy

NIH investigators and colleagues have discovered that when the immune system first responds to infectious agents such as viruses or bacteria, a natural brake on the response prevents overactivation.

23 Jun 2020

Experts identify steps to expand, improve serology tests for COVID-19

More than 300 scientists and clinicians from the federal government, industry and academia published a report of their conclusions and recommendations on COVID-19 serology studies online in Immunity.

23 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

FDA approved drugs active against COVID-19

With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.

23 Jun 2020

Researchers develop method to assess mitochondrial respiration in frozen tissues

Scientists led by Dr. Orian Shirihai, director of the metabolism theme at the David Geffen School of Medicine at UCLA, have developed a method for restoring oxygen-consumption activity to previously frozen mitochondria samples, even years after they have been collected.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Dire warning on contamination of water and COVID-19 spread

A recent report by scientists in the United Kingdom and Poland and published on the preprint server medRxiv in June 2020 describes the presence of stable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in water for up to 25 days, with the risk of infection by the contaminated water varying by the country’s environment.

22 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Electron News and Research

Study identifies small molecule inhibitors of SARS-CoV-2 which block key cellular kinases

Mathematical model reveals the risk of SARS-CoV-2 infection after fecal microbiota transplantation

Interactive cloud-based data portal provides access to treasure trove of pediatric solid tumor data

Study shows how two proteins provide a tunnel for bad cholesterol to enter the cells

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

SARS-CoV-2 has been evolving for at least 7 years

Pixatimod is active in lab studies against SARS-CoV-2

SARS-CoV-2 can replicate in human pediatric gastric organoids

Immune response variations across the COVID-19 spectrum

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

Structured 'cut-and-paste' design enables streamlined development of SARS-CoV-2 molecular probes

Abnormal findings in testicular tissue of COVID-19 patients, SARS-CoV-2 mostly undetected

Discovery provides a potential target for infectious diseases immunotherapy

Experts identify steps to expand, improve serology tests for COVID-19

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

FDA approved drugs active against COVID-19

Researchers develop method to assess mitochondrial respiration in frozen tissues

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Dire warning on contamination of water and COVID-19 spread

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News